The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Lipid‐lowering drugs and mitochondrial function: effects of HMG‐CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
Open accessAbstract
1 Statins inhibit synthesis of mevalonate, a precursor of ubiquinone that is a central compound of the mitochondrial respiratory chain. The main adverse effect of statins is a toxic myopathy possibly related to mitochondrial dysfunction. 2 This study was designed to evaluate the effect of lipid‐lowering drugs on ubiquinone (coenzyme Q10) serum level and on mitochondrial function assessed by blood lactate/pyruvate ratio. 3 Eighty hypercholesterolaemic patients (40 treated by statins, 20 treated by fibrates, and 20 untreated patients, all 80 having total cholesterol levels >6.0 mmol l−1) and 20 healthy controls were included. Ubiquinone serum level and blood lactate/pyruvate ratio used as a test for mitochondrial dysfunction were evaluated in all subjects. 4 Lactate/pyruvate ratios were significantly higher in patients treated by statins than in untreated hypercholesterolaemic patients or in healthy controls (P<0.05 and P<0.001). The difference was not significant between fibrate‐treated patients and untreated patients. 5 Ubiquinone serum levels were lower in statin‐treated patients (0.75 mg l−1±0.04) than in untreated hypercholesterolaemic patients (0.95 mg l−1±0.09; P<0.05). 6 We conclude that statin therapy can be associated with high blood lactate/pyruvate ratio suggestive of mitochondrial dysfunction. It is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction in muscle cells can lead to altered biochemical parameters such as a higher lactate to pyruvate ratio (L/P ratio), but also to development of myopathic symptoms.(20)”
From Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,807
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA · doi:10.1001/jama.1990.03450010075034 · Cited by 425
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.
Ogasahara, S., Engel, A. G., Frens, D. B., & Mack, D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2379 · Cited by 365
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
Comparison of current methods for high-density lipoprotein cholesterol quantitation.
Warnick, G. R., Cheung, M. C., & Albers, J. J. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.4.596 · Cited by 224
Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H., & MacDonald, J. S. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24759-0 · Cited by 146
Masters, B. A., Palmoski, M. J., Flint, O. P., Gregg, R. E., Wang‐Iverson, D. B., & Durham, S. K. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1058 · Cited by 132
Coenzyme Q 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease
Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O'Connor, D., Sherwin, A. L., Karpati, G., Andermann, F., & Arnold, D. L. (1993) · Neurology · doi:10.1212/wnl.43.5.884 · Cited by 125
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
Watts, G. F., Castelluccio, C., Rice-Evans, C. A., Taub, N. A., Baum, H., & Quinn, P. J. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.11.1055 · Cited by 109
Pravastatin-Associated Inflammatory Myopathy
Schalke, B. C. G., Schmidt, B. L., Toyka, K. V., & Hartung, H. ‐. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270919 · Cited by 104
Laaksonen, R., Ojala, J.-P., Tikkanen, M. J., & Himberg, J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194398 · Cited by 94
Okamoto, T., Fukunaga, Y., Ida, Y., & Kishi, T. (1988) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83129-1 · Cited by 82
Elmberger, P. G., Kalén, A., Lund, E. G., Reihnér, E., Eriksson, M., Berglund, L., Angelin, B., & Dallner, G. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41990-x · Cited by 72
Experimental Lovastatin Myopathy
Waclawik, A. J., Lindal, S., & Engel, A. G. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00012 · Cited by 67
LOVASTATIN, ISOPRENES, AND MYOPATHY
Walravens, P., Greene, C. L., & Frerman, F. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91108-2 · Cited by 66
Rhabdomyolysis and Simvastatin
Deslypère, J. P., & Vermeulen, A. T. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-4-342_1 · Cited by 57
Chariot, P., Monnet, I., Mouchet, M., Rohr, M., Lefaucheur, J., Dubreuil‐Lemaire, M., Chousterman, M., & Gherardi, R. K. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370421 · Cited by 55
Self-citationMaltese, W. A., & Aprille, J. R. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39062-2 · Cited by 53
Experimental simvastatin-induced myopathy in rabbits
Nakahara, K., Kuriyama, M., Yoshidome, H., Nagata, K., Nagado, T., Nakagawa, M., Arimura, K., Higuchi, I., & Osame, M. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90273-n · Cited by 44
Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat
Lőw, P., Andersson, M., Edlund, C., & Dallner, G. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90081-6 · Cited by 41
Mitochondrial myopathy ?A result of clofibrate/etofibrate treatment?
Bardosi, A., Scheidt, P., & Goebel, H. (1985) · Acta Neuropathologica · doi:10.1007/bf00688640 · Cited by 16
Contermans, J., Smit, J. W. A., Bär, P. R., & Erkelens, D. W. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04420.x · Cited by 11
Cholesterol lowering agent myopathy
Karasoy, H., Yüceyar, N., ŞİRİN, H., & Ara̧c, N. (2001) · Cited by 6
Research works printed but not linked: 3
- Chariot P, Ratiney R, Ammi Said M, He ´rigault R, Adnot S, d'Instruction des Arme ´es du Val de Gra ˆce, Paris, for cholesterol measurements, and D. Gouiffes, for excellent technical Gherardi R. Optimal handling of blood samples for routine measurement of lactate and pyruvate. Arch Pathol L ab assistance. Med 1994; 118: 695-697.
- Lactate, pyruvate, and ketone bodies. In T echniques in 2 Stalenhoef AFH, Mol MJT, Stuyt PMJ. Efficacy and diagnostic human biochemical genetics: a laboratory manual, tolerability of simvastatin. Am J Med 1989; 87 (4A): ed. Homme P, Wiley-Liss, New-York. 1991: 285-308. 39S-43S.
- Deslypere JP, Vermeulen A. Rhabdomyolysis and simvasta- J Chromatogr 1985; 342: 35-46. tin. Ann Intern Med 1991; 114: 342.
Cited by
Sorted by citations
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 799
The toxicology of perfluorooctanoate
Kennedy, G. L., Butenhoff, J. L., Olsen, G. W., O'Connor, J. C., Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., & Farrar, D. G. (2004) · Critical Reviews in Toxicology · doi:10.1080/10408440490464705 · Cited by 742
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Metadata
- Authors
- DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R.
- Affiliations
- Hôpital Albert-Chenevier (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Corresponding author
- CHARIOT, P.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 42
- Issue
- 3
- Pages
- 333-337
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC2042680
- OpenAlex
- W2095119347
- Cited by
- 262
- References
- 26
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 6 · 2023: 1 · 2022: 2 · 2021: 9 · 2020: 4 · 2019: 8 · 2018: 10 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 6 · 2012: 18
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, mitochondrial dysfunction, coenzyme Q10, lactate/pyruvate ratio, statin-induced myopathy, hypercholesterolemia, fibrates, lipid-lowering drugs, mevalonate
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Mitochondria, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Pyruvic Acid, Lactic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
